Connor's Cure Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2009
NCT01130077
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

hla-a2 restricted glioma antigen-peptides (1 trial)

poly-iclc (2 trials)

Drugs in Other Trials (1)

hla-a2 restricted glioma antigen peptides vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3